The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
The Retina As A Chemogenetic Target For The Treatment Of Depression
Funder
National Health and Medical Research Council
Funding Amount
$408,768.00
Summary
Treatments for depression are often poor because they lack selectivity. By inserting receptors that respond to an inert drug, Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) can turn on-or-off very specific classes of cells, providing an exciting treatment direction for depression and other neuropsychiatric diseases. The long term goal of this project is to create a highly effective DREADD-based treatment for depression, which is activated by either eye drops or a pill.
Combinatorial Therapeutics In High-risk Infant Acute Lymphoblastic Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$340,891.00
Summary
Modern therapies for children with leukaemia are curative in more than 90%. In contrast, survival for infants less than one year of age at the time of diagnosis is less than 50%. Better therapies are desperately needed. From laboratory testing we have discovered effective novel cancer drugs, which are not currently used for treatment of babies with leukaemia. We will evaluate novel drug combinations and test them in model systems, such that they can be fast-tracked to the clinic.
IMPROVING PULMONARY TUBERCULOSIS (TB) OUTCOMES: Investigating Novel Adjunctive Immunotherapies And Addressing HIV-TB Co-infection In Papua, Indonesia
Funder
National Health and Medical Research Council
Funding Amount
$217,846.00
Summary
Tuberculosis remains a major regional and global problem, especially in resource-limited settings such as Australia’s northern neighbours. Three key challenges are to make TB cure easier by shortening treatment, improve HIV-TB co-infection management, and tackle drug resistance. We address these issues in Indonesia’s Papua Province, where we are testing whether simple supplements given with TB treatment might accelerate cure; improving HIV care in people with TB, and detecting drug-resistant TB.
Developing New Therapies To Combat Tuberculosis Through Inhibition Of Vitamin B5 Metabolism In The Organism That Causes The Disease
Funder
National Health and Medical Research Council
Funding Amount
$311,760.00
Summary
The metabolism of vitamin B5 by pathogenic microorganisms has been recognised as an attractive target for developing drugs to combat various infectious diseases. The aim of the proposed work is to develop inhibitors of vitamin B5 metabolism in the bacterium that causes tuberculosis, using a powerful, multidisciplinary approach known as “fragment-based drug discovery”. This work is likely to yield potent inhibitors of the target bacterium, which could ultimately be used to treat tuberculosis.
Elucidating The Mechanisms By Which Bis(thiosemicarbazone)-copper Complexes Protect Neurons In Models Of Neurodegenerative Diseases
Funder
National Health and Medical Research Council
Funding Amount
$353,377.00
Summary
Dr Liddell is a neuroscientist investigating potential therapeutic agents for the treatment of diseases of affecting the brain such as Alzheimer’s disease and Parkinson’s disease. He is examining a class of metal-based compounds that are showing strong potential for disease treatment, and is investigating how these compounds work. The findings will be used to further develop and improve these therapeutic agents, and may help understand the underlying causes of these diseases.